Design Therapeutics, Inc. DSGN
Set alert
10.35 USD +0.20 +1.96%
As of Nov 3, 1:13 PM ET
10.17 Day range 10.58
6.16 52-week range 17.25
- YTD
- +10.33%
- 1 year
- +58.00%
- Open
- 10.24
- Prev close
- 10.15
- Mkt cap
- 648.35M
- Vol
- 54.86K
- Avg vol
- 582.13K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.17
- High
- 10.58
- Forward P/E
- -5.13
- Beta
- 1.83
- Short ratio
- 19.61
- Inst. own
- 56.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 5.88
- 200-d avg
- 4.63
- 1y target
- 7.00
3M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
Analyst view
Price target (mean) 7.00 -32.4% downside
Now 10.35
- Target (low)
- 4.00
- Target (mean)
- 7.00
- Target (high)
- 12.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.26667 | -0.30 – -0.25 | -0.21 | -27.0% | 0 | 0.0% | 3 |
| Next quarter | -0.285 | -0.31 – -0.26 | -0.20 | -42.5% | 0 | 0.0% | 2 |
| Current year | -0.90 | -0.93 – -0.88 | -1.19 | +24.4% | 0 | 0.0% | 3 |
| Next year | -1.21 | -1.31 – -1.04 | -0.90 | -34.8% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| May 7, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| Mar 20, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Mar 20, 2024 | Wedbush | Reiterated | Neutral | Neutral |
| Nov 14, 2023 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Aug 15, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Aug 15, 2023 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 15, 2023 | RBC Capital | Downgrade | Outperform | Sector Perform |
| May 10, 2023 | RBC Capital | Maintained | — | Outperform |
| May 10, 2023 | Wedbush | Maintained | — | Outperform |
| May 4, 2023 | Goldman Sachs | Upgrade | Sell | Neutral |
| Mar 15, 2023 | RBC Capital | Reiterated | — | Outperform |
| Dec 9, 2022 | SVB Leerink | Maintained | — | Outperform |
| Dec 8, 2022 | RBC Capital | Maintained | — | Outperform |
| Aug 9, 2022 | Wedbush | Maintained | — | Outperform |
| Jun 10, 2022 | Wedbush | Initiated | — | Outperform |
| May 24, 2022 | Goldman Sachs | Maintained | — | Sell |
| May 10, 2022 | SVB Leerink | Maintained | — | Outperform |
| May 2, 2022 | RBC Capital | Initiated | — | Outperform |
| Jan 19, 2022 | Goldman Sachs | Initiated | — | Sell |
| Apr 20, 2021 | SVB Leerink | Initiated | — | Outperform |
| Apr 20, 2021 | Goldman Sachs | Initiated | — | Neutral |
| Apr 20, 2021 | Piper Sandler | Initiated | — | Overweight |